07:00 , Jul 30, 2012 |  BC Week In Review  |  Clinical News

Bisnorcymserine: Phase I started

QR Pharma began a double-blind Phase I trial to evaluate single ascending-doses of 20, 40, 80, 160, 380, 490 and 600 mg bisnorcymserine in up to 56 healthy elderly volunteers. The company has exclusive, worldwide...
07:00 , May 30, 2011 |  BioCentury  |  Emerging Company Profile

QR: Power of positivity

QR Pharma Inc. has in-licensed a pair of compounds for cognitive impairment and Alzheimer's disease it believes have suffered from neglect rather than a lack of efficacy or safety. The more advanced of the two...
07:00 , Jul 15, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Cholinesterase A SAR study suggests that molecules combining cholinesterase inhibition with antioxidant activity could help treat AD. In vitro, a series of...
07:00 , Sep 29, 2008 |  BC Week In Review  |  Company News

TorreyPines neurology news

TorreyPines will seek development partners for tezampanel, NGX426 and NGX267. Tezampanel, an AMPA/kainite receptor antagonist, has completed Phase II testing to treat migraine. NGX426, an oral prodrug of tezampanel, is in a Phase I trial...
02:52 , Nov 8, 2005 |  BC Extra  |  Company News

Axonyx to drop phenserine

AXYX said it will discontinue development of phenserine. The announcement follows three failed Phase III trials and one failed Phase IIb trial to treat Alzheimer's disease (AD) ( see BioCentury Extra, Tuesday Sept. 20, 2005...